Description
The dissociation between functional recovery (gBOLD-CSF) and persistent structural damage (ALPS index) suggests distinct pathophysiological processes. This mechanistic gap is critical for understanding which aspects of glymphatic dysfunction are reversible versus permanent.
Gap type: unexplained_observation Source paper: Changes in the cerebral glymphatic system after rehabilitation of COVID-19 patients: A five-year follow-up study. (2026, European journal of radiology, PMID:41442881)
Evidence summary
{“resolution_pipeline”: “scidex.atlas.gap_closure_pipeline”, “task_id”: “f4f7b129-0f43-4c84-abd8-20d4e701842d”, “evaluated_at”: “2026-04-28T19:10:40.268743+00:00”, “resolution_summary”: “Resolved by hypothesis h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27: CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration. Supporting evidence includes debate sess_SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5_20260413-235122.”, “match_counts”: {“hypothesis_matches”: 1, “debate_matches”: 5, “paper_matches”: 0}, “hypothesis_matches”: [{“id”: “h-SDA-2026-04-26-gap-20260426-001521-03-csf-plasma-aqp4-polarization-index-as-a-novel-bi-3c3fec6b27”, “title”: “CSF/Plasma AQP4 Polarization Index as a Novel Biomarker of Astrocyte Glymphatic Failure in Early Neurodegeneration”, “score”: 0.23, “reason”: “5 token overlaps; entity overlap: csf”, “analysis_id”: “SDA-2026-04-26-gap-20260426-001521”, “target_gene”: “AQP4”, “target_pathway”: null, “disease”: null, “composite_score”: 0.7050000000000001, “confidence_score”: 0.498, “status”: “proposed”, “pubmed_evidence_ids”: [“24179313”, “27371494”, “30561329”, “30842439”, “34499128”]}], “debate_matches”: [{“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5_20260413-235122”, “title”: “The study shows that MCT1 disruption leads to axon degeneration and neuron death, but the specific molecular pathways linking lactate transport dysfunction to neuronal damage remain unexplained. Understanding this mechanism is critical for developing targeted neuroprotective therapies.\n\nGap type: unexplained_observation\nSource paper: Oligodendroglia metabolically support axons and contribute to neurodegeneration. (2012, Nature, PMID:22801498)”, “score”: 0.394, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5”, “quality_score”: 0.82, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5_20260414-001952”, “title”: “The study shows that MCT1 disruption leads to axon degeneration and neuron death, but the specific molecular pathways linking lactate transport dysfunction to neuronal damage remain unexplained. Understanding this mechanism is critical for developing targeted neuroprotective therapies.\n\nGap type: unexplained_observation\nSource paper: Oligodendroglia metabolically support axons and contribute to neurodegeneration. (2012, Nature, PMID:22801498)”, “score”: 0.394, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-170325-196c7ee5”, “quality_score”: 0.78, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-15-gap-pubmed-20260411-080155-ea072afc”, “title”: “The abstract shows that Gal3 binding to pTau greatly enhances tau fibrillation, but the specific molecular interactions and structural changes driving this enhancement are not explained. Understanding this mechanism is critical for developing targeted therapeutics that could disrupt this pathogenic interaction.\n\nGap type: unexplained_observation\nSource paper: Galectin-3 aggravates microglial activation and tau transmission in tauopathy. (2024, The Journal of clinical investigation, PMID:37988169”, “score”: 0.39, “reason”: “11 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-15-gap-pubmed-20260411-080155-ea072afc”, “quality_score”: 0.92, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59_20260414-005547”, “title”: “The abstract reports extraordinary dopamine increases (>500-fold in drug-free patients) but provides no mechanistic explanation for how Atremorine achieves this effect. Understanding these mechanisms is critical for optimizing therapeutic applications and predicting safety profiles.\n\nGap type: unexplained_observation\nSource paper: Atremorine in Parkinson’s disease: From dopaminergic neuroprotection to pharmacogenomics. (2021, Med Res Rev, PMID:34106485)”, “score”: 0.385, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-13-gap-pubmed-20260410-145531-5c4e7b59”, “quality_score”: 0.67, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}, {“id”: “sess_SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2_task_9aae8fc5”, “title”: “While the abstract identifies AQP4 as a ‘potential and promising target’ and mentions it could provide ‘new therapeutic alternatives,’ the specific approaches for therapeutic modulation of AQP4 function are not defined. This represents a critical translational gap for moving from mechanistic understanding to clinical intervention.\n\nGap type: open_question\nSource paper: Aquaporin-4 in glymphatic system, and its implication for central nervous system disorders. (2023, Neurobiol Dis, PMID:36796590)”, “score”: 0.381, “reason”: “10 token overlaps; entity overlap: pmid”, “analysis_id”: “SDA-2026-04-07-gap-pubmed-20260406-041445-7e1dc0b2”, “quality_score”: 0.76, “status”: “completed”, “target_artifact_id”: null, “target_artifact_type”: null}], “paper_matches”: []}